Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
National Health Service England has been criticised after announcing its decision that it will not be providing the HIV treatment Truvada, which enables pre-exposure prophylaxis.   2 June 2016
Americas
Law firm Fox Rothschild has hired Patrick Birde, Deborah Somerville and Christopher Glynn as partners in the firm’s intellectual property practice.   2 June 2016
Americas
A pending case at the US Court of Appeals for the Federal Circuit may give the pharmaceutical and biotechnology industry important guidance on issues surrounding third-party contract manufacturing and the on-sale bar to patentability, as Porter Fleming and Jason Kanter of Frommer Lawrence & Haug report.   2 June 2016
Big Pharma
With the UK set to decide on whether it wants to be in or out of Europe, Jane Wainwright and Tom Harding of Potter Clarkson examine how politics is shaping IP in Europe.   2 June 2016
article
Minesoft’s Chemical Explorer helps users to find chemical information in patents issued by multiple authorities. Robert Poolman explains how it works.   2 June 2016
Americas
Jazz Pharmaceuticals, based in Ireland, will buy US company Celator Pharmaceuticals for $1.5 billion in cash.   1 June 2016
Americas
The US Supreme Court has refused to review Cubist Pharmaceuticals’ infringement case over the antibiotic drug Cubicin.   1 June 2016
Americas
Pay-for-delay agreements, otherwise known as reverse settlements, stand at the intersection of intellectual property and competition law, but the clarity hoped for after Actavis has not yet arrived. LSIPR investigates.   1 June 2016
Big Pharma
Despite several major EU rulings on supplementary protection certificates, national IP offices and courts can form differing interpretations, and it seems that a unitary-style SPC right would be hard to create. LSIPR reports.   1 June 2016
Americas
In 2015 the US Federal Circuit resolved the biosimilars case of Amgen v Sandoz. But the parties did not stop there, meaning the Supreme Court could potentially review it. LSIPR looks at the consequences of a possible review.   31 May 2016